Balancing Public Health and Ethical Concerns: A Legal Perspective on Unregulated COVID-19 Clinical Trials in India

Abstract

Clinical trials do form an integral part of pharmaceutical research advances, but the conduct of their activities in India raises highly serious ethical, legal, and social problems, especially in the aftermath of the COVID-19 outbreak. Supported by the cost-efficient structure, regulatory leniencies, and diversified patient pool, India quickly became a global hub of pharmaceutical research after the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into effect in 2005. However, the pandemic merely exposed the oversight of such laxity as the uncontrolled trials disproportionately harmed marginalized people. Strong legal and ethical safeguards are urgently needed, as evidenced by problems like abuse of vulnerable groups and lack of informed consent. The study explores the socioeconomic inequities inherent in the clinical trial process, drawing attention to the disproportionate impact on marginalized communities who were often subjected to trials without adequate protection. The paper thoroughly analyzes India’s current legal framework, which comprises the Drugs and Cosmetics Act, 1940; the New Drugs and Clinical Trials Rules, 2019; and international guidelines. It critically examines gaps in accountability and enforcement, especially
during public health emergencies, and their implications for human rights and medical ethics. Further, the research sheds light on the clinical trial ecosystem in India by exploring relevant topics, such as informed consent, participant protection, and transparency. It points out how vital it is to incorporate national laws with the best global practices to ensure ethical conduct and fair outcomes. The results are aimed at aiding the development of a robust legal framework that safeguards participant rights and encourages public health improvement in the pharmaceutical industry in India.